Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pellets

Drug Development and Industrial Pharmacy

Volumn 36, Issue 4, 2010, Pages 393-404

  Bendas, Ehab R ^a,b   Christensen, J Mark ^a   Ayres, James W ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Delayed release; Eudragit S; Extrusion spheronization; Gelatin; Mesalamine; Tableted reservoirtype pellets

Indexed keywords

EUDRAGIT; GELATIN; MESALAZINE; STARCH GLYCOLATE SODIUM; STEARIC ACID; DELAYED RELEASE FORMULATION; DRUG IMPLANT; EXCIPIENT; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMETHACRYLIC ACID DERIVATIVE; TABLET;

ARTICLE; COLON; DELAYED DRUG RELEASE; DELAYED RELEASE FORMULATION; DISSOLUTION; DRUG CAPSULE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG PELLET; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; IN VITRO STUDY; PELLET EXTRUSION; SPHERONIZATION; STOMACH PH; TABLET COMPRESSION; TABLET FORMULATION; TABLET RESERVOIR TYPE PELLET; TARGET ORGAN; ULCERATIVE COLITIS; WEIGHT GAIN; ANALYSIS; CHEMISTRY; DRUG IMPLANT; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; TABLET;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EXCIPIENTS; MESALAMINE; POLYMETHACRYLIC ACIDS; TABLETS;

EID: 77749268084     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903213717     Document Type: Article

References (30)

1. Gisbert JP, Gomollon F, Mate J, Pajares JM. (2002). Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: A systematic review. Dig Dis Sci, 47:471-88.
2. Klotz U. (2000). The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol, 56:353-62.
3. De Vos M. (2000). Clinical pharmacokinetics of slow release mesalazine. Clin Pharmacokinet, 39:85-97.
4. Peppercorn MA, Goldman P. (1973). Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology, 64:240-5.
5. Nielsen OH, Bondesen S. (1983). Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol, 16:738-40.
6. Schröder H, Campbell DES. (1972). Absorption, metabolism and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther, 13:539-51.
7. RxList. Rowasa. http://www.rxlist.com/cgi/generic/mesal-cp.htm [accessed August 28, 2009]
8. Hardy JG, Healey JNC, Reynolds JR. (1987). Evaluation of an enteric coated, delayed release 5-ASA tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 1:273-80.
9. Hvidberg EF. (1986). GI tract conditions and topical/systemic availability of 5-aminosalicylic acid in a slow release preparation (Pentasa). Acta Pharmacol Toxicol, 59(5):206.
10. Digenis GA, Sandefer EP, Parr AF, Beihn R, McClain C, Scheinthal BM, et al. (1990). Gastrointestinal behavior of orally administered radiolabeled erythromycin pellets in man as determined by gamma scintigraphy. J Clin Pharmacol, 30(7):621-31.
11. Hardy JG, Lamont GL, Evans DF, Haga AK, Gamst ON. (1991). Evaluation of an enteric-coated naproxen pellet formulation. Aliment Pharmacol Ther, 5:69-75.
12. Rudolph MW, Klein S., Beckert TE, Petereit H, Dressman JB. (2001). A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm, 51:183-90.
13. Chuong MC, Christensen JM, Ayres JW. (2009). Sustained delivery of intact drug to the colon: Mesalamine formulation and temporal gastrointestinal transit analysis. Pharm Dev Tech, 14(1):119-28.
14. Bodmeier R. (1997). Tableting of coated pellets. Eur J Pharm Biopharm, 43:1-8.
15. El-Gazaerly ON, Rakkanka V, Ayres JW. (2004). Novel chewable sustained release tablets containing verpamil hydrochloride. Pharm Dev Technol, 9(2):181-8.
16. Bansal P, Vasiredoy S, Plakogiannis F, Parikh D. (1993). Effect of compression on the release properties of polymer coated niacin granules. J Control Release, 27:157-63.
17. Bodmeter R, Paeratakul O. (1994). Properties of dry and wet cellulosic and acrylic polymer films prepared from aqueous colloidal polymer dispersions. Pharm Res, 11(6):882-8.
18. Palsmeier RK, Radzik DM, Lunte CE. (1992). Investigation of the degradation mechanism of 5-aminosalicylic acid in aqueous solution. Pharm Res, 9(7):933-8.
19. Harrison PJ, Newton JM, Rowe RC. (1984). Convergent flow analysis in the extrusion of wet powder masses. J Pharm Pharmacol, 36:796-8.
20. Christensen LA, Fallingborg J, Abildgaard K, Jacobsen BA, Sanchez G, Hansen SH, et al. (1990). Topical and systemic availability of 5-aminosalicylate: Comparisons of three controlled release preparations in man. Aliment Pharmacol Ther, 4:523-33.
21. Khan KA, Rooke DJ. (1976). Effect of disintegrant type upon the relationship between compressional pressure and dissolution efficiency. J Pharm Pharmacol, 28:633-6.
22. Gebre Mariam T, Winnemoller M, Schmidt PC. (1996). Evaluation of the disintegration efficiency of a sodium starch glycolate prepared from enset starch in compressed tablets. Eur J Pharm Biopharm, 42(2):124-32.
23. Gordon MS, Chowhan ZT. (1987). Effect of tablet solubility and hygroscopicity on disintegrant efficiency in direct compression tablets in terms of dissolution. J Pharm Sci, 76:907-9.
24. Kaiho F, Luessen HL, Lehr CM, Verhoef JC, Junginger HE. (1996). Disintegration and gel forming behavior of carbomer and its sodium salt used as excipients for direct compression. STP Pharma Sci, 6(6):385-9.
25. Bolhius GK, Zuurman K, Te-Wierik GH. (1997). Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegrant. Part 2. Choice of super disintegrants and effect of granulation. Eur J Pharm Sci, 5(2):63-9.
26. Joachim J, Kalantzis G, Joachim G, Reynier JP, Piccerelle P, Ruiz JM. (1994). Pregelatinized starches in wet granulation: Experimental design and data analysis. Part 2. Case of tablets. STP Pharma Sci, 4(6):482-6.
27. Wan LSC, Prasad KPP. (1989). Uptake of water by excipients in tablets. Int J Pharm, 50:147-53.
28. Abbaspour MR, Sadeghi F, Afrasiabi Garekani H. (2008). Design and study of ibuprofen disintegrating sustained-release tablets comprising coated pellets. Eur J Pharm Biopharm, 68:747-59.
29. Lundqvist AEK, Podczeck F, Newton JM. (1997). Influence of disintegrant type and proportion on the properties of tablets produced from mixtures of pellets. Int J Pharm, 147:9-107.
30. Debunne A, Vervaet C, Mangelings D, Remon JP. (2004). Compaction of enteric-coated pellets: Influence of formulation and process parameters on tablet properties and in vivo evaluation. Eur J Pharm Sci, 22:305-14.